Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 7/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15964663 | 0.88 | MAPT (0.48) | PTGER1GAAKMT2ACYP1A2AURKA | |
| SCHEMBL15964665 | 0.86 | CYP1A2 (0.54) | PTGER1GAAKMT2ACYP1A2NPC1 | |
| SCHEMBL29831851 | 0.86 | CYP1A2 (0.54) | PTGER1GAAKMT2ACYP1A2NPC1 | |
| SCHEMBL4683999 | 0.84 | PTGER1 (0.51) | PTGER1CA9CA12CA1CA2 | |
| SCHEMBL252003 | 0.84 | PTGER1 (0.51) | PTGER1 | |
| SCHEMBL4085683 | 0.84 | PTGER1 (0.51) | PTGER1CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3180834 | 0.84 | SLC22A12 (0.47) | PTGER1GAAKMT2ACYP1A2RAB9A | |
| SCHEMBL4684067 | 0.83 | TP53 (0.43) | CA9CA12CA1CA2CA7 | |
| SCHEMBL1233306 | 0.83 | SMN1; SMN2 (0.60) | PTGER1GAAKMT2ACYP1A2AURKA | |
| SCHEMBL15050228 | 0.82 | PTGER1 (0.47) | PTGER1CA9CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675832-B1 | HETEROCYCLYL COMPOUNDS | GLAXO GROUP LTD (GB) | 2008-02-20 | — | — | EP | disclosed |
| US-20070060596-A1 | Heterocyclyl compounds | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
| US-20070060596-A1 | Heterocyclyl compounds | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060596-A1 | Heterocyclyl compounds | F9, F12, CYP2C9 | PTGER1 1257/4885CA9 203/4885CA12 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.